10-Q: Collegium Pharma Q3 2025 Earnings Soar on Jornay PM Growth

Collegium Pharmaceutical, Inc. reported a significant increase in net income and product revenues for the third quarter of 2025, driven primarily by strong performance of Jornay PM following its acquisition.

Summary

• Net product revenues for the three months ended September 30, 2025, increased by $50.1 million to $209.4 million, up 31.4% from $159.3 million in the prior year quarter.
• Net income for the three months ended September 30, 2025, significantly increased to $31.5 million, up 237.5% from $9.3 million in the same period last year.
• Diluted earnings per share for the quarter rose to $0.84, compared to $0.27 in the third quarter of 2024.
• Jornay PM revenue saw a substantial increase of $33.8 million, reaching $41.8 million, primarily due to its acquisition in September 2024.
• Belbuca, Nucynta Products, Xtampza ER, and Symproic also contributed to revenue growth in the quarter.
• Adjusted EBITDA for the three months ended September 30, 2025, was $133.0 million, a 26.5% increase from $105.1 million in the prior year quarter.
• For the nine months ended September 30, 2025, net product revenues increased by $125.6 million to $575.1 million, up 27.9% from $449.5 million in the prior year period.
• Net income for the nine months ended September 30, 2025, decreased to $45.9 million from $56.7 million in the prior year period, primarily due to higher operating expenses and interest expense, partially offset by the absence of debt extinguishment losses.
• Net cash provided by operating activities for the nine months ended September 30, 2025, was $206.3 million, a significant increase from $120.3 million in the prior year period.
• The company ended the period with $285.9 million in cash, cash equivalents, and marketable securities.

Sentiment

Score: 7

Explanation: The company demonstrated strong quarterly financial performance with significant revenue and net income growth, driven by Jornay PM. Cash flow from operations also improved substantially. However, the nine-month net income declined due to increased expenses, and the company faces numerous ongoing legal proceedings and regulatory risks, which temper the overall positive sentiment.

Positives

• Product revenues, net, for the three months ended September 30, 2025, increased by $50.1 million to $209.4 million, a 31.4% increase year-over-year.
• Net income for the three months ended September 30, 2025, surged by $22.2 million to $31.5 million, representing a 237.5% increase.
• Diluted earnings per share for the quarter increased to $0.84 from $0.27 in the prior year.
• Jornay PM, acquired in September 2024, contributed significantly to revenue growth with a $33.8 million increase in the quarter.
• Adjusted EBITDA for the three months ended September 30, 2025, grew by $27.9 million to $133.0 million, a 26.5% increase.
• Net cash provided by operating activities for the nine months ended September 30, 2025, increased substantially by $86.0 million to $206.3 million.
• The company's cash, cash equivalents, and marketable securities increased to $285.9 million as of September 30, 2025, from $162.8 million at December 31, 2024.
• A new share repurchase program of up to $150.0 million was authorized through December 31, 2026, demonstrating confidence in financial health and commitment to shareholder returns.

Negatives

• Net income for the nine months ended September 30, 2025, decreased by $10.7 million to $45.9 million, a 19.0% decline compared to the prior year period.
• Diluted earnings per share for the nine months ended September 30, 2025, decreased to $1.28 from $1.51 in the prior year period.
• Interest expense increased by $3.4 million for the three months and $11.7 million for the nine months ended September 30, 2025, primarily due to the deferred royalty obligation from the Ironshore Acquisition and higher principal balance on term loans.
• Interest income decreased by $0.2 million for the three months and $4.5 million for the nine months ended September 30, 2025, due to lower interest rates and a lower overall balance invested.
• Selling, general and administrative expenses increased by $69.9 million for the nine months ended September 30, 2025, largely due to additional headcount and sales/marketing expenses for Jornay PM, as well as executive transition expenses.

Risks

• Ability to maintain profitability is dependent on successfully commercializing current and future products.
• Substantial outstanding indebtedness ($581.3 million 2024 Term Loan, $241.5 million 2029 Convertible Notes) may adversely affect business and financial condition, requiring significant cash flow for debt service.
• Adverse developments in the financial services industry could impair access to funding sources and credit arrangements.
• Additional data may emerge that could change FDA's position on product labeling, including abuse-deterrent claims for Xtampza ER.
• Opioid products (Belbuca, Xtampza ER, Nucynta Products) are subject to mandatory Risk Evaluation and Mitigation Strategy (REMS) programs, increasing costs and potentially reducing willingness of healthcare providers to prescribe.
• Failure to comply with ongoing governmental regulations for marketing products, especially Xtampza ER's abuse-deterrent labeling, could lead to sanctions or claims.
• Unfavorable outcomes in intellectual property litigation could be costly and limit ability to commercialize products, including ongoing suits against Purdue, Alvogen, and Chemo Research.
• Inability to obtain or maintain intellectual property rights for technologies or products may result in loss of valuable assets or inability to compete effectively.
• Reliance on a sole or limited number of third-party manufacturers and suppliers for active pharmaceutical ingredients (APIs) and finished products poses risks of production problems, supply shortages, and increased costs.
• Dependence on wholesale pharmaceutical distributors for retail distribution means loss of significant distributors or disruption to their network could adversely affect financial condition.
• Products containing controlled substances (Jornay PM, Xtampza ER, Nucynta Products, Belbuca) are subject to stringent DEA regulations, including production quotas, which could limit commercial supply.
• Current and future legislation and regulatory changes, such as opioid stewardship taxes, drug pricing transparency laws, and healthcare reform, may increase costs and reduce product prices.
• Social issues around opioid and stimulant abuse, including law enforcement concerns and negative publicity, could decrease market potential and adversely impact investor perceptions.
• Approval of generic products with claims that compete with our products could lead to sales decline for branded products.
• Failure to realize anticipated benefits from future acquisitions or successfully integrate them could adversely affect operating results.
• Business may be adversely affected by macroeconomic conditions (recession, inflation) and geopolitical turmoil (conflicts, trade policy changes).
• Security breaches and disruptions to information technology systems could compromise information and expose the company to liability.
• Use of artificial intelligence technologies could expose the company to data privacy and regulatory risks.
• Litigation or regulatory action regarding opioid medications could negatively affect the business, including the David Lickrish arbitration seeking over $500 million and the Walgreen Co. lawsuit seeking over $14 million.
• Substantial competition from other biotechnology and pharmaceutical companies, including new non-opioid analgesics like Vertex's suzetrigine, may impact market share.
• Commercial sales expose the company to expensive product liability claims, and insurance may not be adequate.
• Relationships with customers and payors are subject to anti-kickback, fraud and abuse, and transparency laws, risking criminal sanctions or civil penalties.
• Natural disasters and health epidemics could disrupt operations, and business continuity plans may be inadequate.
• Inadequate funding for government agencies (FDA, DEA, SEC) or government shutdowns could hinder regulatory processes and negatively impact business.
• The price of common stock may be volatile, and anti-takeover provisions could delay or prevent an acquisition.
• Failure to maintain an effective system of internal control over financial reporting could adversely affect investor confidence and stock value.
• Sales of common stock by current shareholders or future issuances could cause dilution and adversely affect stock price.

Future Outlook

The company believes its current cash, cash equivalents, and marketable securities, combined with expected cash inflows from operations, will be sufficient to fund operating expenses, debt service, and capital expenditure requirements under its current business plan for the foreseeable future. However, it acknowledges significant future capital requirements for manufacturing, commercialization, debt repayment, royalties, operating leases, minimum purchase obligations, income taxes, and potential business development transactions. The company also plans to utilize existing cash on hand to fund future share repurchases under the newly authorized $150.0 million program through December 31, 2026.

Management Comments

• Management believes current cash, cash equivalents, and marketable securities, along with expected cash inflows from operations, will fund operating expenses, debt service, and capital expenditure requirements for the foreseeable future.
• Management acknowledges significant future capital requirements for manufacturing, commercialization, debt repayment, royalties, operating lease obligations, minimum purchase obligations, income taxes, deferred royalty obligations, and contingent payments.
• Management plans to utilize existing cash on hand to fund future share repurchases under the 2025-2026 Repurchase Program.

Industry Context

The biopharmaceutical industry faces intense competition, with new non-opioid analgesics entering the market (e.g., Vertex's suzetrigine) potentially impacting demand for opioid products. Regulatory scrutiny on opioid and stimulant sales and marketing practices remains high, with the FDA implementing new safety labeling changes for opioids and increased oversight on advertising. The DEA's control over Schedule II substances, like methylphenidate (Jornay PM's active ingredient), can lead to supply chain disruptions, although the DEA recently increased quotas. Changes in U.S. presidential administration and related executive orders (e.g., on drug pricing) introduce uncertainty and potential for new regulatory challenges or opportunities.

Management Changes

Corporate Governance

Legal Proceedings

• Xtampza ER Litigation (Purdue): Ongoing patent infringement suits. PTAB found 961 patent invalid. Other patents (933, 919, 434) litigation stayed. Purdue seeks monetary relief, FDA approval adjustment, and injunction.
• Nucynta Litigation (Purdue): Patent infringement suit, currently stayed due to Purdue's bankruptcy.
• Opioid-Related Request and Subpoenas: From various state Attorneys General (Washington, New Hampshire, Maryland). Settled with Massachusetts AG in December 2021. Company is cooperating with remaining states.
• Alvogen Litigation (Belbuca): Patent infringement. Court upheld validity of 866 and 539 patents, enjoining Alvogen until December 21, 2032. A new notice letter from Alvogen claiming non-infringement of 539 patent led to a new patent infringement lawsuit filed July 24, 2025, triggering a thirty-month stay on FDA approval.
• Chemo Research, S.L. (Belbuca): Patent infringement. Bound by Alvogen decision on BEMA patents. Chemo amended its ANDA and received multiple Complete Response Letters from FDA, indicating ongoing delays.
• David Lickrish, as legal assignee of North Sound Pharmaceuticals, Inc. (In Official Liquidation): Request for Arbitration filed May 2025 against Ironshore Pharmaceuticals & Development, Inc. (a subsidiary), seeking compensatory damages in excess of $500 million for alleged contract violation and business torts.
• Walgreen Co. v. Collegium Pharmaceutical, Inc. (Xtampza and Nucynta): Lawsuit filed June 2025, alleging over $14 million in credits owed for product returns between 2020 and 2023. Company filed a motion to dismiss and tendered defense to a third party.

Stakeholder Impact

• Shareholders: Potential for increased share value due to strong Q3 performance and new share repurchase program, but also risk of volatility from ongoing litigation and regulatory changes. Dilution risk from equity compensation plans.
• Employees: Increased headcount due to Ironshore Acquisition, leading to higher salaries, wages, and benefits. Stock-based compensation is a significant part of compensation strategy.
• Customers/Patients: Potential impact from FDA labeling changes for opioid and ADHD products, and potential supply chain disruptions for controlled substances.
• Suppliers: Continued reliance on sole or limited suppliers for active pharmaceutical ingredients creates supply chain risk.
• Creditors: Debt covenants and variable interest rates on the 2024 Term Loan expose the company to interest rate risk and potential default if covenants are not met.
• Regulatory Authorities: Ongoing scrutiny and investigations related to opioid sales and marketing practices, and compliance with REMS programs.

Next Steps

• Continue commercializing and growing sales of existing products, especially Jornay PM.
• Defend intellectual property rights in ongoing patent infringement litigations (Purdue, Alvogen, Chemo Research).
• Vigorously defend against legal claims, including the David Lickrish arbitration and Walgreen Co. lawsuit.
• Manage compliance with evolving governmental regulations, including FDA labeling changes for opioids and ADHD medications, and DEA controlled substance quotas.
• Execute the newly authorized $150.0 million share repurchase program through December 31, 2026.
• Evaluate potential business development transactions, including acquisitions, collaborations, licensing arrangements, and equity investments.

Key Dates

Recommendation

The company demonstrated robust financial performance in Q3 2025, with significant year-over-year increases in net product revenues (+31.4%) and net income (+237.5%), largely driven by the successful integration and growth of Jornay PM. Cash flow from operating activities for the nine-month period also saw a substantial improvement. The authorization of a new $150 million share repurchase program signals management's confidence and commitment to shareholder value. While the nine-month net income shows a decline, this is primarily attributable to increased investments in commercialization and one-time expenses related to the Ironshore acquisition and executive transitions, rather than a fundamental weakness in core operations. The ongoing legal and regulatory challenges are notable, but the company has a history of vigorously defending its intellectual property and managing these risks. The strong underlying business growth and positive cash generation make Collegium Pharmaceutical an attractive investment, warranting a 'buy' recommendation for investors seeking exposure to a growing biopharmaceutical company with a diversified product portfolio.

Keywords

Biopharmaceutical, ADHD, Pain Management, Opioid, Jornay PM, Belbuca, Xtampza ER, Nucynta, Pharmaceutical, SEC Filing, 10-Q, Earnings, Revenue, Net Income, EBITDA, Debt, Litigation, Intellectual Property, Share Repurchase, Controlled Substances, FDA, DEA